Renaissance Bio’s Pharmaceutical Division focuses on the development of
innovative biopharmaceutical solutions that improve patients’ lives and redefine therapeutic standards.
S C R O L L
D O W N
Renaissance Bio’s Pharmaceutical Division focuses on the development of innovative biopharmaceutical solutions that improve patients’ lives and redefine therapeutic standards.
IMD(Incrementally Modified Drug)
Renaissance Bio is actively engaged in global business development and licensing for Incrementally Modified Drugs (IMDs)—
innovative formulations and delivery systems developed to enhance the safety, efficacy, and patient convenience of existing therapeutics.
Through strategic partnerships, Renaissance Bio aims to expand access to improved pharmaceutical solutions that bridge the gap between established molecules and next-generation treatments, strengthening our global network in the field of advanced drug development.
IMD (Incrementally Modified Drug)
Renaissance Bio is actively engaged in global business development and licensing for Incrementally Modified Drugs (IMDs)—
innovative formulations and delivery systems developed to enhance the safety, efficacy, and patient convenience of existing therapeutics.
Through strategic partnerships, Renaissance Bio aims to expand access to improved pharmaceutical solutions that bridge the gap between established molecules and next-generation treatments, strengthening our global network in the field of advanced drug development.
Oncology
Our expertise in the field of oncology enables us to offer a diverse portfolio of innovative treatments and therapies that address various cancer types and stages.
By partnering with us for oncology license out, companies gain access to state-of-the-art cancer treatments and novel therapies, enhancing their product pipeline and expanding their market reach.
We are committed to making a significant impact on cancer care and patient outcomes through the successful licensing of our oncology technologies worldwide.
Oncology
Our expertise in the field of oncology enables us to offer a diverse portfolio of innovative treatments and therapies that address various cancer types and stages.
By partnering with us for oncology license out, companies gain access to state-of-the-art cancer treatments and novel therapies, enhancing their product pipeline and expanding their market reach.
We are committed to making a significant impact on cancer care and patient outcomes through the successful licensing of our oncology technologies worldwide.
Opthalmology
Our expertise in the field of oncology enables us to offer a diverse portfolio of innovative treatments and therapies that address various cancer types and stages.
By partnering with us for oncology license out, companies gain access to state-of-the-art cancer treatments and novel therapies, enhancing their product pipeline and expanding their market reach.
We are committed to making a significant impact on cancer care and patient outcomes through the successful licensing of our oncology technologies worldwide.
Ophthalmology
Renaissance Bio is leading global business development and licensing activities for advanced ocular implant technologies that enable sustained and targeted delivery of therapeutic agents within the eye.
Through strategic partnerships and commercialization expertise, we aim to expand innovative treatment options in the ophthalmic therapeutics field,
strengthening our position as a trusted bridge between pioneering technologies and international markets.
Transdermal Drug Delivery Systems
Renaissance Bio is engaged in strategic licensing and commercialization of advanced transdermal drug delivery systems, offering non-invasive, controlled-release therapeutic solutions across the skin barrier.
Our transdermal platforms integrate material science and formulation expertise to optimize drug permeability, stability, and sustained release, broadening the horizon of systemic and localized drug delivery.
Through active collaboration with global partners, Renaissance Bio is shaping the future of next-generation transdermal therapeutics.
Renaissance Bio is engaged in strategic licensing and commercialization of advanced transdermal drug delivery systems, offering non-invasive, controlled-release therapeutic solutions across the skin barrier.
Our transdermal platforms integrate material science and formulation expertise to optimize drug permeability, stability, and sustained release, broadening the horizon of systemic and localized drug delivery.
Through active collaboration with global partners, Renaissance Bio is shaping the future of next-generation transdermal therapeutics.
